PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald James Molloy - Alliance Global Partners Leland Gershell - Oppenheimer & Co. Joseph Pantginis - H. C. Wainwright & Co. Robert LeBoyer - Noble Capital ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or othe ...

INVESTOR PRESENTATION NASDAQ: PDSB| June 2022 S PDS Biotechnology Precision Designed Science For Immunotherapy Forward-Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals ...

PDS Biotechnology Corporation. (NASDAQ:PDSB) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Hello and welcome to PDS Biotechnology First Qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other juri ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2021 Results Earnings Conference Call March 31, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer James Molloy - Alliance Global Partners Joseph Pantginis - H. C. Wainwright Robert LeBoyer - Noble Capital Markets Oper ...

INVESTOR PRESENTATION NASDAQ: PDSB| March 2022 PDS Biotechnology Precision Designed Science For Immunotherapy Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than statements of historical facts ...

CORPORATE OVERVIEW NOVEMBER 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than st ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2021 Results Conference Call November 10, 2021 8:00 AM ET Company Participants Deanne Randolph - Vice President of Commercial Development Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Lauren Wood - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer Emanuela Branchetti - H. C. Wainwright Operator Greetings and welcome to PDS Biotechnology’s Third Quarter 2021 Earning ...